1887

Abstract

A chimeric type 1/type 2 poliovirus (v510), in which the antigenic site 1 (Ag1) of poliovirus type 1 (PV-1) Mahoney was replaced by the corresponding site of poliovirus type 2 (PV-2) Lansing, is known to be neurovirulent for mice and neutralized by both type 1 and type 2 monoclonal antibodies. Neutralization-escape mutants to monoclonal antibodies specifically recognizing the PV-2 sequence were obtained from v510. The nucleotide sequence and the mouse neuro-virulence of mutants were determined. Amino acid substitutions obtained inside the replaced sequence, at positions 95 and 99, and outside this site, at positions 93 or 104, rendered the virus attenuated for mice. One of the escape mutants harboured a deletion of the entire substituted nonapeptide sequence in v510. This particular virus, which is a PV-1 Mahoney lacking the natural Ag1 loop, does not react with PV-2-specific monoclonal antibodies, has a ts phenotype, is heat-labile and is devoid of neurovirulence for mice.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-72-4-973
1991-04-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/72/4/JV0720040973.html?itemId=/content/journal/jgv/10.1099/0022-1317-72-4-973&mimeType=html&fmt=ahah

References

  1. Almond J. W. 1987; The attenuation of poliovirus neurovirulence. Annual Review of Microbiology 41:153–180
    [Google Scholar]
  2. Blondel B., Crainic R., Fichot O., Dufraisse G., Candrea A., Girard M., Horaud F. 1986; Mutation conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can belocated outside or inside the antibody binding site. Journal of Virology 57:81–90
    [Google Scholar]
  3. Burke K. L., Evans D. J., Jenkins O., Meredith J., D’Souza E. D. A., Almond J. W. 1989; A cassette vector for the construction of antigen chimaeras of poliovirus. Journal of General Virology 70:2475–2479
    [Google Scholar]
  4. Colbere-Garapin F., Christodoulou C., Crainic R., Garapin A. C., Candrea A. 1988; Addition of a foreign oligopeptide to the major capsid protein of poliovirus. Proceedings of the National Academy of Sciences, U,. S,. A 85:8668–8672
    [Google Scholar]
  5. Crainic R., Couillin P., Blondel B., Cabau N., Boue A., Horodniceanu F. 1983; Natural variation of poliovirus neutralization epitope. Infection and Immunity 41:1217–1225
    [Google Scholar]
  6. Evans D. J., McKeating J., Meredith J. M., Burke K. L., Katrak K., John A., Ferguson M., Minor P. D., Weiss R. A., Almond J. W. 1989; An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature, London 339:385–388
    [Google Scholar]
  7. Geliebter J., Azeff R., Melvold R. W., Nathenson S. G. 1986; Mitotic recombination in germ cells generated two major histocompatibility complex mutant genes shown to be identical by RNA sequence analysis: Kbm9 and Kbm6 . Proceedings of the National Academy of Sciences, U,. S,. A. 83:3371–3375
    [Google Scholar]
  8. Hogle M. J., Chow M., Filman J. D. 1985; Three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229:1358–1365
    [Google Scholar]
  9. Horaud F., Crainic R., Van der Werf S., Blondel B., Wychowski C., Akacem O., Bruneau P., Couillin P., Siffert O., Girard M. 1987; Identification and characterization of a continuous neutralization epitope (C3) present on type 1 poliovirus. Progress in Medical Virology 34:129–155
    [Google Scholar]
  10. Jenkins O., Cason J, Burke K. L., Lunney D., Gillen A., Patel D., McCance D. J., Almond J. W. 1990; An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16. Journal of Virology 64:1201–1206
    [Google Scholar]
  11. La Monica N., Kupsky W. J., Racaniello V. R. 1987; Reduced mouse neurovirulence of poliovirus type 2 Lansing antigenic variants selected with monoclonal antibodies. Virology 161:429–437
    [Google Scholar]
  12. Martin A., Wychowski C., Couderc T., Crainic R., Hogle J., Girard M. 1988; Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice. EMBO Journal 7:2839–2847
    [Google Scholar]
  13. Minor P. D. 1987; Structure of picornavirus coat proteins and their antigenicity. In The Molecular Biology of the Positive-Strand RNA Viruses pp 259–280 Edited by Rowlands J. D., Mayo M. A., Mahy B. W. J. London: Academic Press;
    [Google Scholar]
  14. Minor P. D., Ferguson M., Evans D. M. A., Almond J. W., Icenogle J. P. 1986; Antigenic structure of polioviruses of serotypes 1, 2 and 3. Journal of General Virology 67:1283–1291
    [Google Scholar]
  15. Murdin A. D., Wimmer E. 1989; Construction of a poliovirus typel/type2 antigenic hybrid by manipulation of neutralization antigenic site II. Journal of Virology 63:5251–5257
    [Google Scholar]
  16. Murray M. G., Bradley J., Yang X. F., Wimmer E., Moss E. G., Racaniello V. R. 1988a; Poliovirus host range is determined by a short amino acid sequence in neutralization antigenic site 1. Science 241:213–215
    [Google Scholar]
  17. Murray M. G., Kuhn R. J., Arita M., Kawamura N., Nomoto A., Wimmer E. 1988b; Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys. Proceedings of the National Academy of Sciences, U,. S,. A. 85:3203–3207
    [Google Scholar]
  18. Racaniello V. R. 1987; Viral sequences required for neurovirulence of poliovirus. BioEssays 5:266–270
    [Google Scholar]
  19. UytdeHaag F., Osterhaus A. 1985; Induction of neutralizing antibody in mice against poliovirus type II with monoclonal antibodies. Journal of Immunology 134:1225–1229
    [Google Scholar]
  20. Wimmer E., Emini E. A., Diamond D. C. 1986; Mapping neutralization domains of viruses. In Concepts in Clinical Pathogenesis vol 2 pp 159–173 Edited by Notkins A. L., Oldstone M. B. A. New York: Springer-Verlag;
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-72-4-973
Loading
/content/journal/jgv/10.1099/0022-1317-72-4-973
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error